Our Management Team
Mr. Harper has operated numerous successful medical technology companies in his entrepreneurial career. He was President and CEO of ATI Medical (implanted cobalt palladium rods to ablate cancers), which was funded by Domain Associates, Proquest Ventures and Johnson & Johnson Development Corp.
Prior to ATI he was Executive Chairman of Meretek Diagnostics (diagnostic breath tests using isotope labeled substrates), which was ultimately acquired by American Standard Companies. Mr. Harper also served as President and CEO of Índigo Medical (medical lasers), where he led a successful merger with Johnson & Johnson Ethicon EndoSurgery.
Mr. Harper was also President and CEO of Menlo Care (specialty vascular access and urology devices), which also merged into a division of Johnson & Johnson.
Mr. Allen co-founded RTI Biologics (Nasdaq:RTIX), a medical device company with proprietary technology in orthopedics and tissue regeneration, and led the company’s IPO in August 2000.
In addition to RTIX, he has co-founded several successful medical technology companies, including Axogen (Nasdaq:AXGN)(peripheral nerve regeneration), ViewRay (beam-on MRI-guided radiation therapy devices), OrthoHelix (small bone orthopedics), Optima Neuroscience (neural monitoring technology), RegisterPatient.com (cloud-based patient registration), and HyGreen (a spinoff company from Xhale that markets a novel electronic hand hygiene monitoring and reminding system).
Mr. Allen also co-founded Synogen, a private equity medical technology venture fund, and Emergent Growth Fund, a technology investment fund. He is a CPA and has served on the boards of numerous companies.
Dr. Melker is a co-founder of Xhale and HyGreen. He received his Ph.D. (Neurobiology) and M.D. degrees from Albert Einstein College of Medicine. After a residency in Pediatrics, and fellowships in Pediatric Cardiology and Critical Care Medicine, he served as Director of Emergency Services at Shands Hospital at the University of Florida College of Medicine, as well as Medical Liaison for the NASA space shuttle program and to the Crystal River Nuclear Power Plant.
He holds the position of Professor of Anesthesiology, Pediatrics and Biomedical Engineering at U.F. and has been Director of the Florida Anesthesiology Computer and Engineering Team (FACET) which develops and licenses medical devices and technologies.
Dr. Melker holds over 50 issued U.S. (and numerous foreign) patents including several for emergency medical devices in use throughout the world, and by the U.S. Special Forces.
Dr. Dennis, also a co-founder of Xhale, is a board-certified anesthesiologist and previously served in various pharmaceutical company executive positions in the San Francisco area.
In addition to his work with Xhale, Dr. Dennis is a professor in the Departments of Anesthesiology, Psychiatry and Pharmacology & Experimental Therapeutics in the College of Medicine at the University of Florida, where he also holds the Joachim S. Gravenstein M.D. Endowed Chair in Anesthesiology. He is also the Director of Nanomedicine at the University of Florida.
He is a co-inventor on numerous patents and has published 162 full length manuscripts and abstracts in peer-reviewed journals and has edited two textbooks.
Mr. Hassie has several years experience in private industry and public accounting. He served as Chief Financial Officer of publicly-held biotechnology companies raising over $45 million through initial public offerings and privately-held medical technology companies raising over $100 million through venture capital financing.
Mr. Hassie was a Senior Manager in the Boston office of Ernst & Young LLP, providing audit and financial consulting services to emerging mid-market companies.
He is a Certified Public Accountant and received a Bachelor of Science degree in Accounting from Bryant University, as well as an MBA in Management and a Master of Science in Taxation from Bryant University.
Mr. Crumb has extensive experience with medical device companies in both the private equity and publicly traded sectors. His specialties are in lean manufacturing, project management, product development and driving profitability.
His experiences are both domestic and international. As an ex-patriot, he recently managed the construction and startup of a large medical manufacturing operation in Chihuahua, Mexico. Mr. Crumb then returned to the U.S. to manage multiple manufacturing facilities in NY, MX and CA for ConMed Corporation. Mr. Crumb also led manufacturing operations, quality assurance and engineering for DHD Healthcare and IZI Medical Products, successfully transitioning both medical device manufacturers from private equity holdings to new ownership.
Mr. Crumb earned his Masters in Advanced Engineering from the State University of New York in 1999.
Mr. Bigger has over 20 years of experience building shareholder value in pharmaceutical companies globally. He was President and CEO of Paratek Pharmaceuticals, Inc. since 1999, which focuses on discovery, development, and commercialization of innovative medicines for serious diseases.
Prior to Paratek, Mr. Bigger held senior positions at two Biotechnology Companies Magainin Pharmaceutcals and Advanced Polymer Systems that specialized in developing novel therapeutics for serious diseases. Earlier in his career he was a Division President at Rhone-Poulenc Rorer.
Mr. Bigger received a Bachelor of Science degree in Biology and Chemistry from Fairleigh Dickinson University.
Dr. Wohltjen focuses on applying the latest advances in microsensor technologies to the analysis of exhaled breath as a diagnostic matrix. Trained as both an electrical engineer and a chemist, Dr. Wohltjen has been actively engaged in the development and commercialization of novel chemical sensing devices and systems since 1976.
In the 1980’s he formed the Chemical Microsensor research group at the US Naval Research Lab that pioneered a number of important advances in chemical sensor technology. Later he founded Microsensor Systems, Inc. (MSI) and led the commercial development of Surface Acoustic Wave (SAW) microsensors for detecting chemical warfare threats.
Dr. Baumgartner has extensive experience at Merck, spanning more than 14 years and nine different positions in marketing, sales, medical strategies, and strategic planning. At Merck, she maximized the performance of pharmaceutical brands, successfully launched breakthrough pharmaceutical products and vaccines in diverse markets, and optimized communications related to some of the most influential scientific and clinical data of the past decade.
Dr. Baumgartner graduated from the University of Florida in 1996, earning her Doctor of Pharmacy and Master of Business Administration degrees with highest honors.
She has been recognized with numerous awards and accolades throughout her career at Merck, including the Vice President’s Distinguished Service Award, Marketer of the Year Award, Best Customer Program Award, Customer Focused Award, Special Achievement Awards for Outstanding Leadership, and numerous Awards for Excellence.
Mark Tanner graduated cum laude from Yale with a double major in music and computer science. He has led active musical and computer careers, and was among the first Internet programmers, starting in 1978.
He worked for IBM and Schlumberger before starting his own business. He has provided clients with a broad spectrum of services, ranging from embedded systems to computer forensics. With over 30 years of Internet experience, he now specializes in web-based application architecture and development. He created the HyMarks reporting system used by HyGreen, Inc. in hospitals nationwide.
He is currently the Chairman of Emergent Growth Fund II, a Gainesville-based angel investor fund, and advises numerous startup companies.
Dr. Janet Karlix has over 25 years in successful drug development and clinical trials. Her breadth of experience includes playing a pivotal role in Phase I-IV clinical trials in numerous therapeutic areas. Previously, Dr. Karlix was with Élan Pharmaceuticals, Inc., as Medical Director of Immunology, Gastroenterology and Neurology, National Director for Field Medical Teams (Neurology and Gastroenterology) and played a key role in developing the first FDA directed REMS program. Dr. Karlix was also was a successful leader in new company development, business alliance management and asset transfer from Elan to Jansen Alzheimer’s Research and Immunotherapy, Inc. This was a joint business venture with Johnson and Johnson. Her broad leadership expertise expands across disciplines which resulted in successful drug approvals with some of the most impactful molecules in patient care. Dr. Karlix began her industry career over a decade ago with Genentech where she was influential in the lifecycle management in various roles with Rituxan™, Herceptin™ and Tarceva ™.
Before transitioning to industry, Dr. Karlix was a tenured professor at the University of Florida and Director of Translational Clinical Research. She was a visiting scholar for a year at Harvard College of Medicine and MIT with a focus on immunology, pharmacogenomics and bioinformatics. Dr. Karlix has served on NIH study sections and numerous foundations. She is well published in immunopharmacology. Dr. Karlix graduated from Purdue University College of Pharmacy with a BS and PharmD. She completed an ASHP accredited clinical residency at Medical College of Virginia and Immunology/Oncology Residency at University of TX in San Antonio. Her fellowship was funded via a national fellowship award from ACCP at the University of Pittsburgh with a focus on clinical trials and biomarkers in immunology/transplantation/autoimmune disease and infectious diseases.
John Moscarillo is the VP of Commercial Operations for Xhale Assurance with outstanding credentials and a proven track record in sales, management, channel partnerships and corporate alliances. Mr. Moscarillo brings with him 17 years of valuable industry experience and has earned numerous awards and recognition in a variety of sales, sales training and sales management positions.
Mr. Moscarillo initially joined Xhale in December 2014 as the National Business Development Manager of Xhale SMART. He was promoted to Vice President of Commercial Operations for Xhale Assurance with responsibility for Sales, Business Development and Operations in both national and international markets. Previously, while serving in progressive sales roles with Medtronic, Inc. and Phyiso Control, Inc., Mr. Moscarillo developed clinical expertise in the hospital and pre-hospital markets with an emphasis on Cardiology, ICU, and Emergency Departments. Prior to that, Mr. Moscarillo spent five years in the pharmaceutical sales industry.
Mr. Moscarillo received a Bachelor of Arts degree from Longwood University.